Infusion reactions, also known as acute infusion reactions or infusion-related reactions, are common adverse effects that can occur when a person receives medication intravenously. Infusion reactions ...

Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT ®, a three-fold reduction from 67.4 percent historically seen with standard IRR management ...

The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. The incidence of infusion reactions was 47.7% (n = 31) with the combination ...

Reactions to the infusion of natalizumab (Tysabri) for the treatment of multiple sclerosis (MS) are very uncommon, are usually mild, and nearly always occur during, not after, the infusion, new ...

Monoclonal antibodies (elotuzumab and daratumumab) are the newest class of drugs that have proven to be efficacious antimyeloma agents. Although daratumumab, a CD38 monoclonal antibody, has ...

Survival After Fertility-Sparing Surgery for Early-Stage Cervical Cancer Compared With Nonsparing Surgery: A Nationwide Comparative Study Daratumumab is an anti-CD38 monoclonal antibody used to treat ...

Anti-thymocyte Globulin (ATG) has been used for the treatment of acquired aplastic anemia and to decrease the risk of graft versus host disease (GVHD). It is recommended that the first infusion to be ...

Infusion therapy delivers medication through a needle or catheter and is more effective for some drugs. You may also need an infusion if you can’t take oral medication. Share on Pinterest ...

Common side effects of Leqembi include diarrhea, cough, headache, and infusion-related reactions. These side effects are usually mild, temporary, and manageable. Possible serious side effects include ...

Darzalex (daratumumab) can cause a range of side effects from mild to severe, including infusion reactions, low blood cell counts, and respiratory infections. While most Darzalex side effects are mild ...

--Johnson& Johnson today announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions with ...